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Abstract
Background: Advanced cancer and chemotherapy are both associated with immune system suppression. We
initiated a clinical trial in patients receiving chemotherapy for metastatic colorectal cancer to determine if
administration of GM-CSF in this setting was immunostimulatory.
Methods: Between June, 2003 and January, 2007, 20 patients were enrolled in a clinical trial (NCT00257322) in
which they received 500 ug GM-CSF daily for 4 days starting 24 hours after each chemotherapy cycle. There were
no toxicities or adverse events reported. Blood was obtained before chemotherapy/GM-CSF administration and 24
hours following the final dose of GM-CSF and evaluated for circulating dendritic cells and adaptive immune cellular
subsets by flow cytometry. Peripheral blood mononuclear cell (PBMC) expression of g-interferon and T-bet
transcription factor (Tbx21) by quantitative real-time PCR was performed as a measure of Th1 adaptive cellular
immunity. Pre- and post-treatment (i.e., chemotherapy and GM-CSF) samples were evaluable for 16 patients,
ranging from 1 to 5 cycles (median 3 cycles, 6 biologic sample time points). Dendritic cells were defined as lineage
(-) and MHC class II high (+).
Results: 73% of patients had significant increases in circulating dendritic cells of ~3x for the overall group (5.8% to
13.6%, p = 0.02) and ~5x excluding non-responders (3.2% to 14.5%, p < 0.001). This effect was sustained over
multiple cycles for approximately half of the responders, but tachyphylaxis over subsequent chemotherapy cycles
was noted for the remainder. Treatment also led to a significant reduction in the proportion of circulating
regulatory T-cells (Treg; p = 0.0042). PBMC Tbx21 levels declined by 75% following each chemotherapy cycle
despite administration of GM-CSF (p = 0.02). PBMC g-interferon expression, however was unchanged.
Conclusions: This clinical trial confirms the suppressive effects of chemotherapy on Th1 cellular immunity in
patients with metastatic colorectal cancer but demonstrates that mid-cycle administration of GM-CSF can
significantly increase the proportion of circulating dendritic cells. As the role of dendritic cells in anti-tumor
immunity becomes better defined, GM-CSF administration may provide a non-toxic intervention to augment this
arm of the immune system for cancer patients receiving cytotoxic therapy.
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Tumor infiltration by cells involved in the cellular immune
response appears to correlate with prognosis for patients
with colon cancer, suggesting that the immune system
plays a critical role in patient outcome [1-3]. Following
surgical resection of a colonic tumor, improved overall
survival in patients with early stage (I-III) disease corre-
lates with the extent of immune infiltration of the primary
tumor with dendritic cells and T-cells. The reduced
relapse rate in these patients suggests that sensitization to
tumor antigens and an associated viable cellular immune
response may eradicate microscopic residual disease.
While patients with stage IV (metastatic) colorectal cancer
are generally considered incurable, it is theoretically possi-
ble that stimulation of anti-tumor aspects of the immune
system might positively affect response to therapy and
overall median survival [4], analogous to the phenomenon
noted for earlier stages of this disease. In addition, patients
with advanced cancer are known to have tumor-related
immune suppression and chemotherapy, typically adminis-
tered in this setting, is also immunosuppressive [5,6].
However, the degree of immunosuppression of different
chemotherapy regimens, and the precise effects of che-
motherapy on specific lymphocyte subsets have not been
rigorously defined. Still, for patients with colon cancer,
reversing the innate immune suppression caused by any of
the potential etiologies may be advantageous.
GM-CSF is frequently utilized in cancer patients to aid
in hematopoietic recovery but it also has pleiotropic effects
on components of the immune system, including being a
requisite growth factor for myeloid dendritic cells (DCs)
that play an important role in tumor antigen presentation
and stimulation of immune responses [7]. Our hypothesis
was that GM-CSF would be beneficial for patients with
advanced colorectal cancer by stimulating cellular immune
responses, potentially including Th1 immune responses,
specifically by activating dendritic cells and also might
abrogate chemotherapy induced immunosuppression
common in this patient population. We devised a phase II
trial augmenting standard chemotherapy with mid-cycle
GM-CSF and monitored effects on the circulating dendri-
tic cell and other peripheral blood mononuclear cell
(PBMC) populations along with evaluation of Th1 type
immune responses. The principal endpoints of this study
were biologic in order to provide a potential rationale for
larger studies with survival endpoints including GM-CSF.
Materials & methods
Clinical trial design and conduct
Patients who were receiving chemotherapy for stage IV
colorectal cancer were identified for this study. Enrollment
f o rt h i ss t u d yb e g a ni nJ u n e ,2 0 0 3a n de n d e dJ a n u a r y
2007, with 20 patients enrolled onto clinical trial
NCT00257322. The study was approved by the University
of California, Irvine Institutional Review Board and all
patients signed written informed consent prior to partici-
pation. All research was conducted in compliance with the
Helsinki Declaration for ethical research in humans.
Patients received 500 μg GM-CSF daily for 4 days starting
24 hours after completion of each chemotherapy cycle.
Initial patients received weekly 5-fluorouracil with leucov-
orin (n = 12). With changes in standard of care that
occurred during the conduct of the study, a protocol mod-
ification allowed enrollment of patients receiving biweekly
mFOLFOX6 (5FU, leucovorin, oxaliplatin) chemotherapy
(n = 8). Blood was obtained before chemotherapy/GM-
CSF administration and 24 hours following the final dose
of GM-CSF.
Quantitative Real-time PCR (qRT-PCR)
Blood samples drawn from the patients were immediately
processed for the isolation of PBMCs using Histopaque
1083 (Sigma-Aldrich). Trizol (Invitrogen) was added to
the PBMC pellets and stored at 4°C for subsequent RNA
extraction. cDNA preparation for each RNA sample was
performed using the high capacity cDNA reverse tran-
scription kit (Applied Biosystems). PBMC expression of g-
interferon, T-bet transcription factor (Tbx21), DC-LAMP,
and Wnt 5a by quantitative real-time PCR was performed,
the former two as measures of Th1 immunity. All experi-
mental mRNA were normalized to the housekeeping gene
b-actin mRNA.
Flow cytometry
Standard whole blood staining protocols were used to eval-
uate circulating leukocyte populations. Phlebotomy sam-
ples in EDTA anti-coagulated blood were collected and
individual aliquots of 200 μl of blood were placed into
#2059 tubes (BD Biosciences) and stained with the appro-
priate experimental or isotype control antibodies. Tubes
were then incubated at room temperature (RT) for 60 min-
utes in the dark, with mixing every 15 minutes. RBCs were
lysed with ACK lysis media for 15 minutes at RT and resi-
dual cells pelleted by centrifugation. Supernatant was dis-
carded by aspiration, cells washed and the cell pellet was
resuspended in either 500 μl of staining media (if flow
c y t o m e t r ya n a l y s i si st ob ei m m e d i a t e )o r5 0 %v o l u m eo f
staining media and 50% volume freshly prepared 4% paraf-
ormaldehyde. In the latter case tubes were stored at 4°C in
the dark for no more than 48 hours before flow cytometry
analysis. Calabrite 3, a calibration bead set (BD Biosciences)
were used for standardization of the conditions and com-
pensation controls for the three-color flow cytometry ana-
lysis according to manufacturer’s instructions. Additional
fluorophore controls, CD3-FITC, CD8-PE, CD4-TC, were
used to verify the uniformity of conditions for the analyses.
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Expression of mRNA by real-time PCR was compared,
pre- and post-treatment, with a Wilcoxin matched pairs
signed rank test. Changes in lymphocyte subsets pre-
and post-treatment were compared similarly. Differences
across cycles of chemotherapy/GM-CSF administration
were analyzed for statistical significance by a two-tailed
unpaired t-test with Welch’s correction.
Results
Clinical trial
Twenty patients were enrolled in the clinical trial and pre-
and post-treatment (i.e., chemotherapy and GM-CSF)
samples were evaluable for 16 patients. Samples were
obtained ranging from 1 to 5 cycles with a median of 3
cycles (6 biologic sample time points) overall. There were
no toxicities or adverse events to GM-CSF reported. Initi-
ally, most patients received weekly 5FU/leucovorin though
later, because of changes that occurred in the standard of
care, the protocol was amended to include patients receiv-
ing biweekly mFOLFOX6. No significant differences in
immunologic endpoints were seen between the two
groups. In addition, no patients were removed for study
for hematologic toxicities and there was no increased toxi-
city beyond that seen in other trials with these specific
chemotherapy agents without GMCSF. In all cases,
patients received 4 daily dosages of GM-CSF starting 24
hours after completion of the chemotherapy cycle.
Cellular immune response
Cellular immune responses were quantified through the
evaluation of expression of relevant genes from PBMCs by
qRT-PCR. Expression of mRNA for both DC-lamp, a
transmembrane glycoprotein expressed on mature dendri-
tic cells [8] and Wnt5a, which activates macrophages and
T-cells through its interaction with the cell surface
frizzled-5 receptor [9] were minimally detected in the
patient samples (Figures not shown). g-interferon mRNA
levels remained unchanged with the administration of
GM-CSF after chemotherapy (Figure 1A). g-interferon is
produced by Th1 cells, NK cells and, to a lesser extent,
dendritic cells [10]. However, there was a statistically signif-
icant 1.7 fold decrease in T-bet transcription factor (Tbx21)
mRNA following the administration of GM-CSF after che-
motherapy (p = 0.043; Figure 1B), implicating an overall
decrease in Th1-type cellular immune response [11].
Lymphocyte subsets and dendritic cells
Individual lymphocyte subsets were evaluated by flow
cytometry before and after the administration of che-
motherapy and GM-CSF. The subsets that were evaluated
include: CD4+, CD8 +, CD4+CD25 high (Treg) and CD56
+C D 3 +( N K - T )p o p u l a t i o n s .V alues represent average
percentages of nucleated cells in whole blood samples (n =
23). Significant differences were evaluated with a two-
tailed Wilcoxon Signed rank test. The decrease in CD4
and CD8 T lymphocyte subsets was statistically significant
at p = 0.0064 and p = 0.0012 respectively. The decrease in
the Treg population was also significant at p = 0.0042 and
the decrease in NK-T cells approached statistical signifi-
cance of p = 0.0997 (Figure 2A).
In the first and subsequent cycles of chemotherapy and
GM-CSF the percent change in lymphocyte subsets that
include CD4+, CD8 +, CD4+CD25 high (Treg) and
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Figure 1 Panel A. Levels of g-interferon mRNA following the administration of GM-CSF after chemotherapy. g-interferon mRNA levels were
measured in 16 patients pre-chemotherapy/GM-CSF administration and post-GM-CSF/chemotherapy administration by quantitative real time PCR of
peripheral blood mononuclear cells. g-interferon mRNA levels were normalized against the housekeeping gene b-actin mRNA. There was no
statistically significant change between the two groups. Panel B. Levels of T-bet transcription factor mRNA following the administration of GM-CSF
after chemotherapy. T-bet transcription factor mRNA levels were measured in 16 patients pre-chemotherapy/GM-CSF administration and post-GM-
CSF/chemotherapy administration by quantitative real time PCR of peripheral blood mononuclear cells. T-bet transcription factor mRNA levels were
normalized against the housekeeping gene b-actin mRNA. There was an approximate 1.7 fold decrease in T-bet transcription factor mRNA levels
following the administration of GM-CSF after chemotherapy (p = 0.043). The statistical significance was determined by a Wilcoxin matched pairs test.
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subsets were evaluated by flow cytometry before and after the administration of chemotherapy and GM-CSF. The subsets that were evaluated
include: CD4+, CD8 +, CD4+CD25 high (Treg), CD56+ CD3+ (NK-T) populations. Values depicted represent average percentages of nucleated
cells in whole blood samples (n = 23) with error bars depicting standard error values. Significant differences were evaluated with a Wilcoxon
matched pairs test. The decrease in CD4 and CD8 T lymphocyte subsets was statistically significant at p = 0.0064 and p = 0.0012 respectively.
The decrease in the Treg population was also significant at p = 0. 0042 while the decrease in NK-T cells approached statistical significance p =
0.0997. Panel B. Percent change in lymphocyte subsets across multiple cycles of chemotherapy & GM-CSF. In the first and subsequent cycles of
Chemotherapy & GM-CSF the percent change in lymphocyte subsets that include: CD4+, CD8 +, CD4+CD25 high (Treg), CD56+ CD3+ (NK-T)
populations, were determined. Percent change was calculated in the standard fashion [(pre- treatment value - post-treatment value)/pre-
treatment value] × 100. None of the differences in lymphocyte subset changes between the first and subsequent cycles reached statistical
significance by two-tailed unpaired t-test with Welch’s correction. Panel C. Changes in monocytes and myeloid DCs associated with
chemotherapy and GM-CSF administration. Individual cell populations were evaluated by flow cytometry before and after the administration of
chemotherapy and GM-CSF. Monocyte populations were identified as being CD14+. Myeloid dendritic cells (DCs) were identified using a lineage
cocktail (CD3, CD20, CD14, CD56) negative cells that had MHC II high expression. Values depicted represent average percentages of nucleated
cells in whole blood samples (n = 23) with error bars depicting standard error values. Differences were evaluated with a Wilcoxon matched pairs
test. Differences in monocytes and DCs were statistically significant p = 0.0214 and p = 0.0198 respectively. Panel D. Percent change in
monocytes and dendritic cells across multiple cycles of chemotherapy and GM-CSF. In the first and subsequent cycles of Chemotherapy & GM-
CSF the percent change in monocytes (CD14+ cells) and dendritic cells (DCs) [lineage cocktail (CD3, CD20, CD14, CD56) negative, MHC II high
expression] were determined. Percent change was calculated in the standard fashion [(pre-treatment value - post-treatment value)/pre-treatment
value] × 100. None of the differences in lymphocyte subset changes between the first and subsequent cycles reached statistical significance by
two-tailed unpaired t-test with Welch’s correction.
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cent change was calculated in the standard fashion [(Pre
treatment value-Post treatment value)/pre-treatment
value] × 100. None of the differences in lymphocyte sub-
set changes between the first and subsequent cycles
reached statistical significance by two-tailed unpaired t-
test with Welch’s correction (Figure 2B).
Individual cell populations were evaluated by flow cyto-
metry before and after the administration of chemotherapy
and GM-CSF. Monocyte populations were identified as
being CD14+. Myeloid DCs were identified using a lineage
cocktail (CD3, CD20, CD14, CD56) negative cells that had
MHC II high expression. Values represent average percen-
tages of nucleated cells in whole blood samples (n = 23).
There were statistically significant increases in both mono-
cytes (p = 0.0214) and DCs (p = 0.01980) following che-
motherapy and GM-CSF (Figure 2C). Overall, there was
no difference between the first and subsequent cycles of
chemotherapy and GM-CSF in the percent change in
monocytes (CD14+ cells) and DCs (lineage cocktail (CD3,
CD20, CD14, CD56) negative, MHC II high expression;
Figure 2D). However, approximately 50% of the patients
exhibited increased dendritic cell numbers in subsequent
chemotherapy/GM-CSF cycles.
Discussion
GM-CSF is utilized primarily for its activity in increasing
granulocyte production following administration of bone
marrow suppressive cytotoxic chemotherapy. However,
largely because of its role in stimulating monocytic precur-
sors, it has long been recognized that it possesses immu-
nostimulatory activity [7]. Our utilization of GM-CSF in
this trial was to attempt to abrogate the immunosuppres-
sion induced by chemotherapy [5] and by the cancer itself
[6]. In this population of patients receiving chemotherapy
for metastatic colorectal cancer, GM-CSF was adminis-
tered without significant toxicity.
GM-CSF did not augment cellular, Th1, immune func-
tioning, as measured by the methodologies utilized in this
study. The reduction in T-bet is postulated to be second-
ary to chemotherapy. The lack of concomitant reduction
of g-interferon may be due to GM-CSF-dependent stimu-
lation of dendritic cells, which can also produce this cyto-
kine. Together with the decreases in the CD4+, CD8+,
CD14+ and CD56 =/CD3+ populations, the decrease in T-
bet suggests that there was not selective sparing of Th1
biased lymphocytes by the cytotoxic chemotherapy to
account for the stable g-interferon mRNA expression in
PBMCs. As there was no control arm of patients receiving
chemotherapy without GM-CSF on this study, we cannot
quantitate the absolute reduction in PBMC g-interferon
production which might be seen following chemotherapy
alone. With respect to T-cell subset changes, approxi-
mately 2/3 (66%) of subjects had a significant decrease in
CD4+ lymphocytes and approximately 80% of subjects
had a significant decrease in CD8+ lymphocytes with each
cycle.
One of the most significant findings from this clinical
trial was the increase in the number of circulating myeloid
DCs (Lineage-, MHC high). These increased in approxi-
mately 75% of subjects across all cycles. In subsequent
cycles of chemotherapy and GM-CSF, approximately 50%
of the subjects experienced increased DC numbers over
the initial cycle. Dendritic cells are potent antigen present-
ing cells and play a pivotal role in the induction of
immune responses. Dendritic cells have been directly
implicated in anti-tumor immune responses [12-15]. The
increase in circulating DCs, likely a consequence of GM-
CSF administration, may contribute to the anti-tumor
effects of chemotherapy administered in the adjuvant or
metastatic setting.
Another important observation was the reduction in
regulatory T-cells (Treg) following chemotherapy/GM-
CSF. Approximately 90% of subjects had a significant (>
20%) decrease in Treg lymphocytes with the first cycle.
Tregs can suppress the activity of cytotoxic T cells
through direct cell-to-cell contact or via the release of
cytokines such as transforming growth factor beta. Deple-
tion of intratumoral Tregs has been shown to enhance
antitumor immunity and promote tumor rejection in
mouse models [16]. In patients with colon cancer,
increased numbers of Treg cells has been associated with
a poor clinical prognosis [17]. This decrease in circulating
Treg cells argues against a significant increase in myeloid
derived suppressor cells, implicated in the induction of
Tregs [18], as a result of the administration of GM-CSF;
an effect that has been inconsistently reported in other set-
tings[19-22]. Thus, the reduction in Tregs seen in our
study, and the concomitant loss of immune system sup-
pression that these cells induce, may be prognostically
favorable.
As noted previously, this study did not contain a che-
motherapy only control arm. Therefore, the effects of che-
motherapy cannot be distinguished specifically from the
effects of GM-CSF. Still, in patients with metastatic color-
ectal cancer receiving chemotherapy and GM-CSF, cellular
immune responses are inhibited and the impairment in
Th1 type immune parameters are not abrogated by admin-
istration of GM-CSF. However, administration of GM-CSF
along with chemotherapy does lead to an increase in circu-
lating DCs and a reduction in inhibitory Tregs. Together,
this may provide a mechanism for augmentation of innate
immune responses and may provide benefit to colorectal
cancer patients receiving chemotherapy.
Conclusions
This phase II clinical trial confirms that chemotherapy
in patients with metastatic colorectal cancer suppresses
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administration of GM-CSF can significantly increase the
proportion of circulating dendritic cells and reduce the
proportion of circulating Treg cells. Th1 activity, as
measured by g-interferon production, was not affected.
These finding suggest that GM-CSF can abrogate
important aspects of the immune suppression seen in
patients with advanced colorectal cancer and may pro-
vide a non-toxic intervention to augment anti-tumor
immunity for cancer patients receiving cytotoxic
chemotherapy.
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